Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 10:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,012 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adverse Events Clear all
Terminated Phase 2 Interventional

Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose

NCT05517668
View directory record Official record
Conditions
Acetaminophen, Drug Overdose, Acetaminophen Overdose, Acetaminophen Poisoning, Drug-induced Liver Injury, Liver Failure, Liver Toxicity
Interventions
Intravenous infusion of N-acetylcysteine, Intravenous infusion of Fomepizole (4-MP)
Drug
Lead sponsor
Richard Dart, MD, PhD
Other
Eligibility
10 Years to 99 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 29, 2026, 10:26 AM EDT
Completed Not applicable Interventional

Multi-hospital Electronic Decision Support for Drug-associated Acute Kidney Injury

NCT06264752
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Level A, Level B, Passive Alert
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
8
States / cities
Altoona, Pennsylvania • Farrell, Pennsylvania • McKeesport, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 29, 2026, 10:26 AM EDT
Terminated Phase 3 Interventional

Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer

NCT00016276
View directory record Official record
Conditions
Cardiac Toxicity, Inflammatory Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer
Interventions
dexrazoxane hydrochloride, doxorubicin hydrochloride, cyclophosphamide, paclitaxel, trastuzumab, therapeutic conventional surgery, radiation therapy, tamoxifen citrate, laboratory biomarker analysis
Drug · Biological · Procedure + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 29, 2026, 10:26 AM EDT
Completed No phase listed Observational

Side Effects of Pulmonary Hypertension Medications

NCT01571713
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
Up to 18 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 29, 2026, 10:26 AM EDT
Completed No phase listed Observational

Predicting Favorable Outcomes in Hospitalized Covid-19 Patients

NCT04570488
View directory record Official record
Conditions
COVID, Corona Virus Infection, Adverse Event
Interventions
EPIC risk score display
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
1,415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Oct 29, 2026, 10:26 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Telerehabilitation Cognitive Impairments Following Chemotherapy Usability Study

NCT04839588
View directory record Official record
Conditions
Chemotherapy-Related Cognitive Impairment, Healthy
Interventions
Usability study
Other
Lead sponsor
Bright Cloud International Corp
Industry
Eligibility
20 Years to 65 Years · Female only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
North Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Oct 29, 2026, 10:26 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

NCT06461897
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Upadacitinib, Dupilumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 11 Years
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
31
States / cities
Little Rock, Arkansas • Palo Alto, California • Sacramento, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 29, 2026, 10:26 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.

NCT07514260
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-295, Placebo for ABBV-295
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 29, 2026, 10:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From 5/45 mg Strength of ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) 45 mg and Rosuvastatin Calcium 5 mg

NCT00826358
View directory record Official record
Conditions
Healthy
Interventions
ABT-143, ABT-335, rosuvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2012 · Synced Oct 29, 2026, 10:26 AM EDT
Terminated Not applicable Interventional

Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients

NCT05812274
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Apricity C.A.R.E. Program for Cancer Adverse events Rapid Evaluation
Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 29, 2026, 10:26 AM EDT
Completed No phase listed Observational

Taste of Medicines in Children

NCT04220918
View directory record Official record
Conditions
Medication Adherence, Medication Reaction
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
3 Years to 12 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Oct 29, 2026, 10:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)

NCT00198458
View directory record Official record
Conditions
Drug Hypersensitivity
Interventions
Vitrase
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2013 · Synced Oct 29, 2026, 10:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Medication Errors and Adverse Drug Events (ADEs) in Ambulatory Pediatrics

NCT00229671
View directory record Official record
Conditions
Pediatric ALL
Interventions
Survey 1, Survey 2
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
1 Day to 21 Years
Enrollment
6,341 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 29, 2026, 10:26 AM EDT
Recruiting Phase 2 Interventional

Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor

NCT07673107
View directory record Official record
Conditions
Upper Limb Essential Tremor
Interventions
AGN-151607-DP, Placebo for AGN-151607-DP
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 85 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
19
States / cities
Carlsbad, California • Fresno, California • Fullerton, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 29, 2026, 10:26 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Acetaminophen Adduct Formation in Non-Drinkers Taking Therapeutic Doses of Acetaminophen for Ten Consecutive Days

NCT00616018
View directory record Official record
Conditions
Drug Induced Liver Injury
Interventions
acetaminophen
Drug
Lead sponsor
Kennon Heard
Other
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 12, 2012 · Synced Oct 29, 2026, 10:26 AM EDT
Completed No phase listed Observational

Spanish Translation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

NCT01436240
View directory record Official record
Conditions
Cancer
Interventions
questionnaire administration followed by cognitive interviews
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
6
States / cities
Los Angeles, California • Miami, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 29, 2026, 10:26 AM EDT
Completed No phase listed Observational

Evaluation of MyoStrain™ in Clinical Practice

NCT03825224
View directory record Official record
Conditions
Cardiac Failure, Coronary Artery Disease, Sarcoidosis, Amyloidosis, Lupus, Myocarditis, Drug Toxicity
Interventions
Diagnostic Test: Myostrain
Procedure
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
Not listed
Enrollment
19 participants
Timeline
2019
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 29, 2026, 10:26 AM EDT
Completed Not applicable Interventional Results available

Imaging Guided Patient Selection for Interventional Revascularization Therapy

NCT00963989
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Penumbra System
Device
Lead sponsor
Penumbra Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 29, 2026, 10:26 AM EDT
Suspended Early Phase 1 Interventional

Sodium Thiosulfate Otoprotection During Salvage Cisplatin Therapy

NCT05756660
View directory record Official record
Conditions
Ototoxicity, Drug-Induced
Interventions
Sodium Thiosulfate
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Month to 39 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 29, 2026, 10:26 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of GTS21 in Adults With Attention-deficit Hyperactivity Disorder

NCT00419445
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
GTS21/Placebo
Drug
Lead sponsor
CoMentis
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2010 · Synced Oct 29, 2026, 10:26 AM EDT
Recruiting No phase listed Observational

Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure

NCT04262830
View directory record Official record
Conditions
Cardiotoxicity, Pediatric Cancer, Heart Failure
Interventions
Cardiac magnetic resonance imaging (MRI), Accelerometer physical activity monitoring
Diagnostic Test · Other
Lead sponsor
Hari Narayan
Other
Eligibility
13 Years to 39 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 29, 2026, 10:26 AM EDT
Recruiting No phase listed Observational

A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy

NCT06647134
View directory record Official record
Conditions
Arthritis, Polymyalgia Rheumatica, Immune Checkpoint Inhibitors
Interventions
Not listed
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 29, 2026, 10:26 AM EDT
Recruiting Phase 3 Interventional

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

NCT07000357
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
AZD0780, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
15,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
357
States / cities
Athens, Alabama • Birmingham, Alabama • Fairhope, Alabama + 284 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 29, 2026, 10:26 AM EDT
Completed Not applicable Interventional

Trial of Cognitive Behavioral Therapy to Reduce Antiretroviral Therapy Side Effects

NCT00696839
View directory record Official record
Conditions
HIV Infections, Adverse Effects
Interventions
Cognitive-behavioral therapy
Behavioral
Lead sponsor
Duquesne University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 29, 2026, 10:26 AM EDT